

Department of Radiation Oncology

Monthly Research Update: August 2026

Identifying Research Funding

AUGUST AT A GLANCE TOTALS

Clinical trials

Total enrolled	22
GCC, other	5
NRG, co-ops	3
PCG, other registries	14

Grants and contracts

New awards	0
Submitted	1

Articles published

12

Information for this monthly update should be provided no later than the second Wednesday of each month to Miek Segers at msegers@som.umaryland.edu. The update will be published on the second Friday of each month.

Have questions about identifying a funding source? Finding research partners across the UMB/UM campuses or at another university? Defining future research strategies? Or organizing your thoughts on (virtual) paper? Contact Nancy Knight, PhD, Director of Academic and Professional Development for the department, at nknight@umm.edu.

Research from members of our department is featured in >60 presentations and other sessions at ASTRO and AAPM this year. The next step for many of our faculty and trainees is to prepare these for publication and, in some cases, to use resulting data to pursue extramural funding. Identifying the right funding source can be challenging. The UMSOM [Center for Advanced Research Training & Innovation](#) (CARTI) offers multiple resources and mentorship on external and internal grants and contracts as well as application preparation.

[Explore NIH Grant Opportunities](#) offers NIH-specific filters and [Search Tips](#) on funding opportunities. Users can [subscribe](#) for new opportunity announcements. Also useful is the NIH [Highlighted Topics](#) page that identifies current research priority areas for NIH components and specific grant mechanisms.

Important Dates for Upcoming Funding Submissions

Updated calendar for **near-term NIH submission deadlines**, with firm due dates for major NIH deadlines (RFA/PA dates may differ). Contact the Department Office of Research Administration (msegers@som.umaryland.edu) ASAP if you plan to submit a proposal, regardless of funder.

R01 10/05 (new)	09/21/2026	09/24/2026	09/28/2026
*R21 10/16 (new)	10/02/2026	10/07/2026	10/09/2026
R01 11/05 (resub)	10/23/2026	10/25/2026	10/29/2026
*R21 11/16 (resub)	11/03/2026	11/07/2026	11/09/2026

¹DORA deadline: All forms to be included in proposal, known or in draft, budget final, subcontractor budgets and information final in final form, 9 business day prior to NIH deadline. ²ORA deadline: Personnel, effort, budget materials, performance site, and compliance forms routed in final form, 7 business days prior to NIH deadline. ³SPA deadline: All proposal materials routed in FINAL form by 5 pm, 5 business days prior to NIH deadline. No more corrections allowed, unless indicated after review by SPA. *R21 deadline is also for R03, R33, R21/R33, R34, R36, UH2, UH3, and UH2/UH3 submissions

Clinical Trial Enrollment

- 14 patients at MPTC on the **Proton Collaborative Group Registry**
- 2 patients at MPTC on **NRG CC015**: Harnessing E-mindfulness approaches for living after breast cancer—HEAL-ABC
- 2 patients at UCH on **GCC 1926**: A phase 1 dose escalation study of single fraction pre-operative partial breast S-PBI for early-stage breast cancer
- 2 patients at UMMC on **GCC 2380**: A single arm phase I-II trial evaluating selective adjuvant therapy for HPV-mediated oropharynx SCCs based on residual circulating tumor DNA (ctDNA) levels (SAVAL)
- 1 patient at MPTC on **GCC 2578**: A phase II, randomized, open-label, single-center study comparing intensity modulated proton therapy versus volume modulated arc therapy in patients receiving pelvic nodal irradiation for newly diagnosed gynecologic primaries
- 1 patient at MPTC on **NRG GU013**: The phase III 'High Five Trial' five fraction radiation for high-risk prostate cancer

Grants and Contracts

Awarded:

None

Submitted:

Erika Davies, PhD, subrecipient PI with Novo Heal, Inc. to NIH/NCI PA-27-102, for “Developing a novel regenerative treatment for radiation-induced fibrosis” (\$212,380).

Articles Published

Entered into PubMed August 9 through September 9. Titles link to PubMed abstracts. Note that this list includes all authors who list their affiliation as our department at UM SOM, regardless of current affiliation.

1. Bentzen SM, Gupta T, Jacinto AA, Rosenblatt E, Bhasker S, Napoles M, Binia S, Chansilpa Y, Aguiar S, Nagarajan M, Laskar SG, De Marchi P, Goloubeva O, Hopkins K, Zubizarreta E, Agarwal JP, Abdel-Wahab M. [In reply to Russi. Int J Radiat Oncol Biol Phys.](#) 2026 Sep 1;126(1):275-276.
2. Bentzen SM, Gupta T, Jacinto AA, Rosenblatt E, Bhasker S, Napoles M, Binia S, Chansilpa Y, Aguiar S, Nagarajan M, Laskar SG, De Marchi P, Goloubeva O, Hopkins K, Zubizarreta E, Agarwal JP, Abdel-Wahab M. [In reply to Saini et al. Int J Radiat Oncol Biol Phys.](#) 2026 Sep 1;126(1):273-274.
3. Chen H, Modiri A, Sawant A. [Stand-alone graph-based lung airway labeling with quantitative validations. Med Phys.](#) 2026 Sep;53(9):e70634.
4. Damani A, Elhusseiny AM, Sinha A, Blair SR, Chen SE, Wang S, Oechsli S, Faria E, Triesler S, Calfee L, Nuon A, Elbash K, Vij S, Magder L, Byrne K, Gibbs A, Jackson IL, Rege A, Saeedi OJ. [Dynamic and structural retinal microvascular alterations after radiation exposure: Insights from a large-animal model. Invest Ophthalmol Vis Sci.](#) 2026 Aug 3;67(10):38.
5. Dutta Chowdhury D, Imada EL, Connis N, Chang J, Chan A, Tseng HW, Lafargue A, Carrieri FA, Nguyen T, Waters DN, Simms ER, Shetty AC, Song Y, Khan MA, Rezaee M, Tran PT, Marchionni L, Hann CL. [TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer. Mol Cancer Ther.](#) 2026 Sep 2;25(9):1550-1562.
6. Ellis RJ, Pugh SL, Yu JB, Feng FY, Konski AA, Grubb RL 3rd, Wallace RE, Gladstone DJ, Ménard C, Miccio JA, Frazier AJ, Pennington JD, Michalski JM, Spratt DE, Martinez A, Morgan SC, Mihai A, Solanki AA, Amjad A, Straza MW, Delouya G, Schroeder TM, Marshall DT, Kapadia N, Patel AN, Cescon TP, El-Gayed A, Yoon HA, Paulus R, Sandler HM; NRG-GU005 Collaborative Authors. [Stereotactic body radiotherapy vs moderately hypofractionated IMRT for localized intermediate-risk prostate cancer: A randomized clinical trial. JAMA.](#) 2026 Aug 13:e2612627. Online ahead of print.PMID: 42593775
7. Forbes N, Irankunda BB, Terrones-Campos C, Smith A, Reekie J, Darkner S, Pøhl M, Risumlund S, Specht L, Bentzen SM, Petersen J, Maraldo MV, Vogelius IR. [Time trends in cardiac doses in 10,000 patients receiving curative thoracic radiation therapy between 2009 and 2020. Clin Oncol \(R Coll Radiol\).](#) 2026 Aug 13;58:104324. Online ahead of print.
8. Li J, Wang F, Li W, Yang C, Setianegara J, Badiyan S, Westover K, Domal S, Lin Y, Gao H. [Exploratory personalized radiobiological modeling of bystander and immune effects to inform SFRT-SBRT scheduling. Med Phys.](#) 2026 Sep;53(9):e70643.
9. Rowell R, Wen CZ, Bzhilyanskaya V, Tong JY, Kaufman AC. [Contemporary treatment patterns in surgically treated temporal bone cancer. Laryngoscope.](#) 2026 Aug 17. Online ahead of print.
10. Shi X, Shetty AC, Wang J, Song Y, Sutera PA, Deek MP, Patel KR, Madan RA, Tang C, Proudfoot J, Davicioni E, Hussain A, Nguyen P, Sweeney C, Boytim E, Lacuna KP, Ryan CJ, Antonarakis ES, Tran PT, Hwang J. [APUC-6 genes as a potential prognostic and predictive biomarker in the CHARTED prostate cancer trial. JCO Precis Oncol.](#) 2026 Aug;10(8):e2501012.
11. Zhang B, Yi B. [Redundancy strategies for cyber resilience in radiation oncology. Semin Radiat Oncol.](#) 2026 Aug 20;39:151053. Online ahead of print.
12. Zheng Z, Luo Y, Chen J, Luo Y. [Myofibroblasts slow down defect recombination dynamics in mixed cell monolayers. J R Soc Interface.](#) 2026 Aug 5;23(241):20260007.